Evaxion A/S ADR (EVAX) — Titan Protect Analysis

EVAX

Evaxion A/S ADR

Healthcare · ·

$3.55

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$30M

Total market value of the company

Trailing P/E

N/A

Forward P/E

89.38

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

-129.6%

How much profit the company keeps from each dollar of revenue

ROE

-82.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.00

+182% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About Evaxion A/S ADR

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a m

https://evaxion.ai

Country: Denmark Employees: 46 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.018

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0178

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.571

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-52.9%

Historical annualised return based on price data

Max Drawdown

-92.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.27

Very low correlation to market moves

52W High

$12.15

71% below the year high

52W Low

$2.07

71% above the year low

Avg Volume

31,898

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.00

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-122.0%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$8M

Total revenue over the last 12 months

Net Income

$-9,756,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$16.00

Target Median

$10.00

Target Low

$9.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go